Ieq Capital LLC Makes New $449,000 Investment in Sana Biotechnology, Inc. $SANA

Ieq Capital LLC bought a new position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 128,792 shares of the company’s stock, valued at approximately $449,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. AQR Capital Management LLC raised its holdings in shares of Sana Biotechnology by 49.8% during the first quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock worth $963,000 after acquiring an additional 190,483 shares during the period. Woodline Partners LP raised its stake in shares of Sana Biotechnology by 13.1% in the 1st quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock valued at $1,312,000 after purchasing an additional 90,515 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Sana Biotechnology by 86.8% in the second quarter. Franklin Resources Inc. now owns 93,081 shares of the company’s stock valued at $254,000 after purchasing an additional 43,247 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Sana Biotechnology by 11.6% during the second quarter. Rhumbline Advisers now owns 203,283 shares of the company’s stock worth $555,000 after buying an additional 21,149 shares during the period. Finally, Prudential Financial Inc. bought a new position in shares of Sana Biotechnology during the second quarter worth about $50,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Price Performance

NASDAQ:SANA opened at $3.93 on Friday. The company has a market cap of $1.18 billion, a P/E ratio of -5.17 and a beta of 2.16. The firm’s fifty day moving average price is $3.57 and its two-hundred day moving average price is $3.42. Sana Biotechnology, Inc. has a one year low of $2.61 and a one year high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. As a group, equities research analysts expect that Sana Biotechnology, Inc. will post -0.72 earnings per share for the current year.

Wall Street Analyst Weigh In

SANA has been the topic of several research reports. Rodman & Renshaw began coverage on Sana Biotechnology in a research note on Monday, May 11th. They issued a “buy” rating and a $16.00 target price on the stock. Wall Street Zen downgraded shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Monday, July 20th. Bank of America cut their price objective on shares of Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Weiss Ratings upgraded shares of Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. Finally, TD Cowen upgraded shares of Sana Biotechnology to a “strong-buy” rating in a research note on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.33.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.